标题
Anti-tumor Activity of Toll-Like Receptor 7 Agonists
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2017-05-31
DOI
10.3389/fphar.2017.00304
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- TRAF6 is a critical factor in fish immune response to virus infection
- (2017) Jingguang Wei et al. FISH & SHELLFISH IMMUNOLOGY
- Cloning and functional characterization of IRAK4 in large yellow croaker ( Larimichthys crocea ) that associates with MyD88 but impairs NF-κB activation
- (2017) Peng Fei Zou et al. FISH & SHELLFISH IMMUNOLOGY
- The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects
- (2017) Liang Ding et al. MOLECULAR CANCER THERAPEUTICS
- Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
- (2017) Lupe G. Salazar et al. JAMA Oncology
- TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
- (2016) Rujuta A. Bam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
- (2016) Ileana S. Mauldin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Poly(I:C) potentiates Bacillus Calmette–Guérin immunotherapy for bladder cancer
- (2016) Cherifa Ayari et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TLR7 Structure: Cut in Z-Loop
- (2016) Kazuhiko Maeda et al. IMMUNITY
- Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line
- (2016) Shi-Wei Huang et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- A video-based educational pilot for basal cell carcinoma (BCC) treatment: A randomized controlled trial
- (2016) Elyse M. Love et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Beneficial effect of low-level laser therapy in acute lung injury after i-I/R is dependent on the secretion of IL-10 and independent of the TLR/MyD88 signaling
- (2016) J. L. Carvalho et al. LASERS IN MEDICAL SCIENCE
- Toll-like receptors signaling: A complex network for NF-κB activation in B-cell lymphoid malignancies
- (2016) Stavroula Ntoufa et al. SEMINARS IN CANCER BIOLOGY
- Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal stem cell-driven tissue regeneration
- (2016) Mikaël M. Martino et al. Nature Communications
- Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy
- (2016) Simon J. Dovedi et al. Oncotarget
- A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity
- (2016) Minakshi Rana et al. Frontiers in Pharmacology
- A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice
- (2016) Gabriela Maria Wiedemann et al. OncoImmunology
- Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma
- (2015) A. H. Rook et al. BLOOD
- TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice
- (2015) Erina Koga-Yamakawa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice
- (2015) Hiroyasu Ito et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial
- (2015) Renata Ursu et al. CANCER SCIENCE
- Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model
- (2015) Hiroyasu Ito et al. IMMUNOLOGY
- Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma
- (2015) Jiang Zhu et al. Journal of Hematology & Oncology
- Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model
- (2015) TAO YIN et al. Molecular Medicine Reports
- Activation of Toll-like receptor 7 inhibits the proliferation and migration, and induces the apoptosis of pancreatic cancer cells
- (2015) BING-BING ZOU et al. Molecular Medicine Reports
- Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation
- (2015) YUWEN DIAO et al. ONCOLOGY REPORTS
- Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects
- (2015) Xiao-Dong Wang WORLD JOURNAL OF GASTROENTEROLOGY
- The TLR7 agonist induces tumor regression both by promoting CD4+T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells
- (2015) Chenchen Wang et al. Oncotarget
- Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors
- (2015) Sebastian Schölch et al. Oncotarget
- Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma
- (2015) R. L. Sabado et al. Cancer Immunology Research
- Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment
- (2015) Valentino Le Noci et al. OncoImmunology
- Toll-like Receptor 3 Regulates Angiogenesis and Apoptosis in Prostate Cancer Cell Lines through Hypoxia-Inducible Factor 1α
- (2015) Alessio Paone et al. NEOPLASIA
- The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma
- (2014) Pallab Pradhan et al. BIOMATERIALS
- Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
- (2014) David A. Smith et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9
- (2014) Yuyi Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
- (2014) D. W. Northfelt et al. CLINICAL CANCER RESEARCH
- A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models
- (2014) Amy L. Adlard et al. INTERNATIONAL JOURNAL OF CANCER
- TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas
- (2014) O. M. Grauer et al. JOURNAL OF IMMUNOLOGY
- Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation
- (2014) Manisha Singh et al. JOURNAL OF IMMUNOLOGY
- The role of TLR8 signaling in acute myeloid leukemia differentiation
- (2014) J J Ignatz-Hoover et al. LEUKEMIA
- A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity
- (2014) Nicholas D. Leigh et al. PLoS One
- GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees
- (2013) Robert E. Lanford et al. GASTROENTEROLOGY
- Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod™
- (2013) Andreas Weber et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Poly(I:C) exhibits an anti-cancer effect in human gastric adenocarcinoma cells which is dependent on RLRs
- (2013) Jing Qu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod
- (2013) JU-HEE HAN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Inhibitory effect of dsRNA TLR3 agonist in a rat hepatocellular carcinoma model
- (2013) YU-YIN XU et al. Molecular Medicine Reports
- IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner
- (2013) Yukino Chiba et al. PLoS One
- Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RAR and tumor regression
- (2013) R. Galli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies
- (2012) Brenda J. Weigel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Toll-like Receptor 5 Agonist Inhibition of Growth of A549 Lung Cancer Cells in Vivo in a Myd88 Dependent Manner
- (2012) Shi-Xiang Zhou et al. Asian Pacific Journal of Cancer Prevention
- Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility
- (2012) Tomoaki Nakamura et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
- (2012) S. J. Dovedi et al. BLOOD
- Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer
- (2012) S. Adams et al. CLINICAL CANCER RESEARCH
- Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer
- (2012) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer
- (2012) Erina Koga-Yamakawa et al. INTERNATIONAL JOURNAL OF CANCER
- Pharmacokinetics of Daily Self-Application of Imiquimod 3.75% Cream in Adult Patients With External Anogenital Warts
- (2012) Jason Wu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Toll-like receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis
- (2012) Mee-Young Ahn et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells
- (2012) Li Chen ONCOLOGY REPORTS
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
- (2012) Erika Vacchelli et al. OncoImmunology
- Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
- (2011) Shangzi Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
- (2011) R. Rosa et al. CLINICAL CANCER RESEARCH
- Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses
- (2011) M. B. Davis et al. CLINICAL CANCER RESEARCH
- Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse
- (2011) A. S. Lee et al. DIABETOLOGIA
- TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells
- (2011) Y. Zhang et al. JOURNAL OF IMMUNOLOGY
- Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma
- (2011) Rupa Narayan et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
- (2010) Melissa A. Geller et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice
- (2010) Fang Ma et al. Cellular & Molecular Immunology
- Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist
- (2010) Thanh Nhan Nguyen Pham et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- The TAK1–TRAF6 signalling pathway
- (2010) Marene Landström INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Intravesical Toll-like receptor 7 agonist R-837: Optimization of its formulation in an orthotopic mouse model of bladder cancer
- (2010) Tomoko Hayashi et al. INTERNATIONAL JOURNAL OF UROLOGY
- Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance
- (2010) Julien Cherfils-Vicini et al. JOURNAL OF CLINICAL INVESTIGATION
- In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
- (2010) Joshua D. Brody et al. JOURNAL OF CLINICAL ONCOLOGY
- TLR-signaling Networks
- (2010) J. Brown et al. JOURNAL OF DENTAL RESEARCH
- Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 Blockade
- (2010) H. Lu et al. JOURNAL OF IMMUNOLOGY
- A Critical Role for Mast Cells and Mast Cell-Derived IL-6 in TLR2-Mediated Inhibition of Tumor Growth
- (2010) S. A. Oldford et al. JOURNAL OF IMMUNOLOGY
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
- (2010) Youn H. Kim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Regression of Established AB1 Murine Mesothelioma Induced by Peritumoral Injections of CpG Oligodeoxynucleotide Either Alone or in Combination with Poly(I:C) and CD40 Ligand Plasmid DNA
- (2010) Geoffrey W. Stone et al. Journal of Thoracic Oncology
- DAMPening Inflammation by Modulating TLR Signalling
- (2010) A. M. Piccinini et al. MEDIATORS OF INFLAMMATION
- Targeting Toll-like receptors: emerging therapeutics?
- (2010) Elizabeth J. Hennessy et al. NATURE REVIEWS DRUG DISCOVERY
- A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine
- (2010) Antonella Conforti et al. VACCINE
- Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
- (2009) Michael Chan et al. BIOCONJUGATE CHEMISTRY
- Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
- (2009) Jonathan W. Friedberg et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells
- (2009) Evelien L. J. M. Smits et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9
- (2009) L. Aurisicchio et al. CLINICAL CANCER RESEARCH
- Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy
- (2009) S. A. Broomfield et al. JOURNAL OF IMMUNOLOGY
- Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of Langerhans Cells Exposed to Human Papillomavirus Type 16
- (2009) L. M. Fahey et al. JOURNAL OF IMMUNOLOGY
- Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists
- (2009) Svetlana Hamm et al. Journal of Immunotoxicology
- Imiquimod Enhances IFN-γ Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin
- (2009) Susan J. Huang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia
- (2009) D E Spaner et al. LEUKEMIA
- TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo
- (2009) Tao Ren et al. PATHOLOGY & ONCOLOGY RESEARCH
- Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma
- (2009) Geoffrey W. Stone et al. PLoS One
- An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models
- (2008) S Dharmapuri et al. CANCER GENE THERAPY
- NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model
- (2008) Calin D. Dumitru et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma
- (2008) R. Dummer et al. CLINICAL CANCER RESEARCH
- TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN
- (2008) Jon R. Inglefield et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- TLR signaling by tumor and immune cells: a double-edged sword
- (2008) B Huang et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started